Liquan Xue

Activating mutations in ALK provide a therapeutic target in neuroblastoma

Rani E. George, Takaomi Sanda, Megan Hanna et al. · Nature · 2008 · 885 citations · Full text

Receptor Tyrosine Kinase, Tumor Suppressor, Radiation Oncology +4

Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)

Quangeng Zhang, Reiner Siebert, Minhong Yan et al. · Nature Genetics · 1999 · 376 citations

Lymphoid Neoplasia, Immunology, Pathology +5

The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors

Hiromitsu Hara, Chitose Ishihara, Arata Takeuchi et al. · Nature Immunology · 2007 · 355 citations

Inflammation, Toll-like Receptors, Immunogenetics +12

Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma

Qian Zhang, Puthryaveett N. Raghunath, Liquan Xue et al. · The Journal of Immunology · 2002 · 261 citations

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Jim Sang, Jaime Acquaviva, Julie C. Friedland et al. · Cancer Discovery · 2013 · 209 citations · Full text